Kezar Life Sciences (NASDAQ:KZR) Trading Up 2.4% – Should You Buy?

Kezar Life Sciences, Inc. (NASDAQ:KZR)’s share price rose 2.4% on Wednesday . The stock traded as high as $6.62 and last traded at $6.39. Approximately 32,828 shares were traded during mid-day trading, a decline of 3% from the average daily volume of 33,745 shares. The stock had previously closed at $6.24.

Wall Street Analyst Weigh In

A number of research firms have issued reports on KZR. William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday, November 13th. Wells Fargo & Company reduced their price objective on Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, December 2nd.

Kezar Life Sciences Stock Up 2.4 %

The firm has a market cap of $46.65 million, a P/E ratio of -0.48 and a beta of 0.19. The business’s fifty day moving average price is $6.61 and its two-hundred day moving average price is $6.75. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.05.

Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.25. As a group, equities research analysts anticipate that Kezar Life Sciences, Inc. will post -4.39 EPS for the current year.

Institutional Investors Weigh In On Kezar Life Sciences

A number of large investors have recently added to or reduced their stakes in KZR. Peapod Lane Capital LLC acquired a new stake in shares of Kezar Life Sciences in the fourth quarter valued at about $833,000. Geode Capital Management LLC grew its holdings in Kezar Life Sciences by 15.0% in the 3rd quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after buying an additional 81,678 shares during the last quarter. XTX Topco Ltd increased its position in Kezar Life Sciences by 256.1% in the 3rd quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after buying an additional 37,504 shares during the period. Ikarian Capital LLC lifted its holdings in shares of Kezar Life Sciences by 23.0% during the third quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after buying an additional 200,000 shares during the last quarter. Finally, Stonepine Capital Management LLC boosted its position in shares of Kezar Life Sciences by 42.0% in the third quarter. Stonepine Capital Management LLC now owns 1,491,305 shares of the company’s stock valued at $1,153,000 after acquiring an additional 440,853 shares during the period. Institutional investors own 67.90% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.